SecProbe.io

August 8, 2024
Jason Coloma, Ph.D.
Chief Executive Officer
Maze Therapeutics, Inc.
171 Oyster Point Blvd.
Suite 300
South San Francisco, CA 94080
Re:Maze Therapeutics, Inc.
Amendment No. 1 to Draft Registration Statement on Form S-1
Submitted July 31, 2024
CIK 0001842295
Dear Jason Coloma Ph.D.:
            We have reviewed your amended draft registration statement and have the following
comments.
            Please respond to this letter by providing the requested information and either submitting
an amended draft registration statement or publicly filing your registration statement on EDGAR.
If you do not believe a comment applies to your facts and circumstances or do not believe an
amendment is appropriate, please tell us why in your response.
            After reviewing the information you provide in response to this letter and your amended
draft registration statement or filed registration statement, we may have additional
comments. Unless we note otherwise, any references to prior comments are to comments in our
July 25, 2024 letter.
Amendment No. 1 to Draft Registration Statement on Form S-1
Prospectus Summary
Our Pipeline, page 2
1.We note your response to comment 4 and reissue the comment. Please note that program
targets constitute material information. To the extent that a program is material, all
material information about the program should be disclosed. To the extent that there are
several targets under consideration, please revise your disclosure to disclose them. Your
additional disclosure on page 128 should be expanded to more specifically describe the
work you have done to date, as opposed to focusing on aspirations and plans.
We note your response to comment 5 and re-issue in part. Please specify your ownership 2.

August 8, 2024
Page 2
percentage with respect to Broadwing Bio. Additionally, file the joint venture agreement
relating to Broadwing Bio as an exhibit to your registration statement.
Our approach to precision medicine: Compass platform, page 4
3.We note your response to comment 11 and re-issue. Please further revise your disclosure
to ensure the text and logos are legible in the graphic.
Exclusive License Agreement, page 94
4.We note your response to comment 16, including your disclosure of Shionogi reversion
royalties on any sales of the Licensed Products in a range of “mid-single digit to lower
double-digit” royalties. Please provide a more defined range that does not exceed ten
percentage points.
Other Partnered Programs, page 128
5.We note your response to comment 15 and are continuing to consider whether these
agreements are required to be filed pursuant to Item 601(b)(10) of Regulation S-K. Due to
your lack of disclosure about the agreements, it is not possible for us to agree with your
response. Regardless of the determination as to whether or not the agreement is required
to be filed, a description of the material terms of the agreements is required. Please revise
your registration statement to provide the following information for each of your
agreements with Neurocrine Biosciences and Trace Neuroscience:
•Describe each parties' rights and obligations under the agreement;
•Provide quantified disclosure of all amounts paid and/or received to date;
•Provide quantified disclosure of all potential regulatory milestone payments;
•Provide quantified disclosure of potential sales based milestone payments, if any;
•Describe any royalty provisions, including the royalty rate within a ten point range
and disclose when the royalty provisions expire; and
•Disclose the term and termination provisions.

Intellectual Property, page 133
6.We note your response to comment 25. Please provide the expiration dates and types of
patents for your U.S. provisional patent applications and foreign patent applications
disclosed on page 135.
            Please contact Sasha Parikh at 202-551-3627 or Kevin Vaughn at 202-551-3494 if you
have questions regarding comments on the financial statements and related matters. Please
contact Jimmy McNamara at 202-551-7349 or Suzanne Hayes at 202-551-3675 with any other
questions.
Sincerely,

August 8, 2024
Page 3
Division of Corporation Finance
Office of Life Sciences
cc:Amanda Rose